You are here

Drug Safety Revisions: FDA Update

Marvin M. Goldenberg, PhD, RPh, MS
PDF version: 
The author reviews the reasons for FDA labeling changes for estrogens and estrogen–progesterone combinations as hormonal therapy; sertraline for depression; and palivizumab as prophylactic therapy for respiratory infections.